National Institute of Arthritis and Musculoskeletal and Skin Diseases 1R41AR084935-01

Development of a Novel Therapeutic Agent for Skin Fibrosis

FibroBiologics, LLC received NIH funding to develop a novel peptide therapeutic, M10, targeting skin fibrosis in scleroderma patients. The project involves laboratory and animal model studies to evaluate antifibrotic activity and dosing, aiming to advance M10 towards clinical trials.

Description

This Phase I STTR project by FibroBiologics, LLC aims to develop the novel peptide M10 as an efficacious antifibrotic therapeutic agent for the treatment of skin fibrosis associated with scleroderma. The project includes in vitro studies on primary skin fibroblasts from scleroderma patients and in vivo efficacy and dosing studies in two animal models of dermal fibrosis. The goal is to provide important information about the feasibility of developing M10 as a novel therapeutic and justify further studies for FDA clearance and clinical trials.

View original record